PARP1 and neoplasm: The PARP inhibitor niraparib significantly suppressed tumor growth in a mouse xenograft model of FOXQ1-expressing OC, suggesting that PARP inhibition may offer therapeutic benefit by targeting FOXQ1 (Wu et al., 2024).